Cost-Effectiveness of Including a Nurse Specialist in the Treatment of Urinary Incontinence in Primary Care in the Netherlands. by Holtzer-Goor, K.M. (Kim) et al.
RESEARCH ARTICLE
Cost-Effectiveness of Including a Nurse
Specialist in the Treatment of Urinary
Incontinence in Primary Care in the
Netherlands
K. M. Holtzer-Goor1*, J. G. Gaultney1, P. van Houten2, A. S. Wagg3, S. A. Huygens1, M. M.
J. Nielen4, C. P. Albers-Heitner5, W. K. Redekop1, M. P. Rutten-van Mölken1, M. J. Al1
1 Erasmus University Rotterdam, Institute for Medical Technology Assessment / Institute of Health Policy
and Management, Rotterdam, The Netherlands, 2 Zonnehuisgroep Amstelland, Medical department,
Amstelveen, the Netherlands, 3 University of Alberta, Department of Medicine, Edmonton, AB, Canada,
4 NIVEL (Netherlands Institute for Health Services Research), Department of General Practice, Utrecht, the
Netherlands, 5 Maastricht University Medical Center, Department of Obstetrics and Gynecology, Maastricht,
the Netherlands
* goor@bmg.eur.nl
Abstract
Objective
Incontinence is an important health problem. Effectively treating incontinence could lead to
important health gains in patients and caregivers. Management of incontinence is currently
suboptimal, especially in elderly patients. To optimise the provision of incontinence care a
global optimum continence service specification (OCSS) was developed. The current study
evaluates the costs and effects of implementing this OCSS for community-dwelling patients
older than 65 years with four or more chronic diseases in the Netherlands.
Method
A decision analytic model was developed comparing the current care pathway for urinary
incontinence in the Netherlands with the pathway as described in the OCSS. The new care
strategy was operationalised as the appointment of a continence nurse specialist (NS)
located with the general practitioner (GP). This was assumed to increase case detection
and to include initial assessment and treatment by the NS. The analysis used a societal per-
spective, including medical costs, containment products (out-of-pocket and paid by insurer),
home care, informal care, and implementation costs.
Results
With the new care strategy a QALY gain of 0.005 per patient is achieved while saving €402
per patient over a 3 year period from a societal perspective. In interpreting these findings it
is important to realise that many patients are undetected, even in the new care situation
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(36%), or receive care for containment only. In both of these groups no health gains were
achieved.
Conclusion
Implementing the OCSS in the Netherlands by locating a NS in the GP practice is likely to
reduce incontinence, improve quality of life, and reduce costs. Furthermore, the study also
highlighted that various areas of the continence care process lack data, which would be
valuable to collect through the introduction of the NS in a study setting.
Introduction
Incontinence, whether urinary or faecal, is a significant health problem worldwide that has a
negative impact on the health and quality of life of patients and their caregivers. In most studies
including adults from all over the world, prevalence rates vary between 11 and 15% for faecal
incontinence and 25% and 45% for urinary incontinence [1]. In the Netherlands, an estimated
800,000 people have some level of incontinence [2], although the actual number could be
higher due to reluctance to seek help. For many people incontinence is a taboo topic that they
find difficult to discuss, even with their general practitioner (GP). People may also not talk
about incontinence because it is thought to be inherent to ageing or because they are unaware
of available treatments [3, 4]. Many people appear to have suffered from incontinence for a
long time prior to the first visit to the GP [3].
Both urinary and faecal incontinence are most common in older persons. However, urinary
incontinence (UI) is far more common with a ratio of 6:2:1 for UI versus faecal incontinence
(FI) versus both [3]. Each year in the Netherlands, approximately 64,000 new patients report to
the doctor with UI [5]. In older people, UI greatly influences quality of life since it is often
accompanied by feelings of shame, depression and low self-esteem. It is also a risk for falls and
is associated with admission to a nursing home [6, 7]. Unfortunately, studies show that, espe-
cially in older patients, care for UI is below standard [8–11]. It is therefore important that fur-
ther efforts be made to ensure that elderly people receive the best care available.
Besides the practical, hygienic and social problems experienced by people with UI, its
chronic nature has a negative impact on the psychological health of caregivers [12, 13] and is
also associated with high costs for health care and society [14]. The economic costs of inconti-
nence absorbing material, diagnostic tests, physiotherapy, surgical procedures and work loss
have been shown to be substantial [15–18]. In 2000, the direct and indirect costs of urinary
incontinence were $19.0 billion and $0.5 billion in the USA, respectively [16]. The direct
annual medical costs of urinary incontinence per inhabitant (€71) are similar to those of coro-
nary heart disease (€78), and higher than the costs of diabetes or refraction errors/accommoda-
tion problems [19].
To improve the standard of care delivery for UI and FI in community dwelling patients and
their health, an optimum continence service specification was developed for use internation-
ally, which aimed to make recommendations on service delivery that would enable care speci-
fied in most national and international clinical guidelines to be delivered [1, 20–22]. The
optimum continence service specification adopted a modular approach that could be adapted
to specific local circumstances [23]. The specification included case detection, initial assess-
ment and treatment, case co-ordination, caregiver support, community-based support, special-
ist assessment and treatment, use of containment products and use of technology.
Cost-Effectiveness of Continence Nurse Specialist
PLOS ONE | DOI:10.1371/journal.pone.0138225 October 1, 2015 2 / 23
employer of KHG; JG; SH; KR; MRM; MA received a
unrestricted grant from SCA. This employer also
received unresticted grants from various
pharmaceutical companies, for various clinical areas,
all not related to this study. PH, SCA: Speaker
honoraria, support for travel; AW, SCA: Speaker
honoraria, support for travel. Astellas Pharma:
speaker honoraria, grant support for research,
consultancy; none associated with this study. Pfizer
Inc: speaker honoraria, grant support for research,
consultancy, none associated with this study. Merus
Labs: speaker honoraria, none associated with this
study. This does not alter the authors’ adherence to
PLOS ONE policies on sharing data and materials.
In the optimum continence service specification four profiles of patients were explored in
detail: stress and urgency UI, faecal incontinence, incontinence because of neurological dis-
eases, and elderly/cognitively impaired. Note that these groups are not necessarily mutually
exclusive. Given the great heterogeneity between the four profiles, one was initially selected for
the purposes of testing the service specification, i.e. elderly/cognitively impaired. This patient
profile was chosen because this population was deemed to have a greater unmet need than
patients in the other profiles. It was operationalised as elderly (>65 years) patients with four or
more co-existent chronic diseases. We focused on UI, because there was insufficient informa-
tion available to conduct the analysis for FI. The patient group we selected often experiences
restrictions in their mobility or cognitive functioning, thereby increasing the number of incon-
tinence episodes. Evidence suggests that these individuals may receive a lower quality of care
than younger people [24, 25]. Moreover, this group of patients already visits the GP practice
for other reasons than incontinence, making them ideally suited for case finding and deploying
follow-up strategies. Additionally, this population is expected to increase further in future
decades.
Alongside improved health and quality of life of incontinent patients, adoption of the opti-
mum continence service specification could also have an impact on the costs of care. For exam-
ple, active detection could lead to increased costs of treatment. At the same time, an increase in
patients successfully treated for incontinence may reduce the costs of medication, containment
products, formal home care use and informal care use. Also, adverse events related to inconti-
nence such as falls, incontinence related skin damage and urinary tract infections may be pre-
vented. Therefore, an economic evaluation was carried out to assess the cost-consequences and
health effects of the possible implementation of the optimum continence service specification
in the Netherlands compared with the current situation.
Patients and Methods
Optimum continence service specification
The implementation of the continence service specification for UI in the Netherlands included
the following changes to the current delivery of care: 1) more active case detection in primary
care by either the primary care physician or a continence nurse specialist (NS); 2) initial assess-
ment and treatment by a continence NS, potentially leading to more successfully treated
patients and more patient and carer centred prescription of containment products; and 3)
improved case coordination by NSs who will liaise with home care agencies (agencies that pro-
vide personal care, [specialised] nursing care, instructions and information, and guidance and
support to patients at home) and both formal and informal caregivers to address the patient’s
medical and non-medical care needs [23]. The type of continence nurse specialist proposed in
this evaluation is someone who is allowed to prescribe drugs and containment products, refer
patients for specialist care and perform physical examinations of the patients.
Patient population
The population of community-dwelling patients older than 65 years with four or more chronic
diseases was defined using a published list of chronic diseases based on ICPC-2 codes (but
recoded to ICPC-1) [26]. This list includes morbidities such as hypertension and obesity,
which might be seen more as risk factors rather than diseases. Combinations of diseases that
are common among elderly in the general population are: hypertension, osteoarthritis, ischae-
mic heart disease, obesity, atherosclerosis and diabetes [27]. Patients who were 65 years or
older with fewer chronic diseases were not included in our analysis, since they are less depen-
dent on formal and informal care.
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The size of the target population was estimated by combining the percentage of eligible
patients per age group and gender group [28] with the number of non-institutionalised Dutch
elderly persons [29] per age and gender group (See Table 1). Incidence and prevalence rates for
UI were those of 219 Dutch general practices participating in NIVEL Primary Care Database in
2012 [30] and the study of Teunissen et al. [3] respectively. UI cases in this group were defined
as patients complaining of any involuntary loss of urine. Although UI varies in terms of sever-
ity and aetiology [1], all UI cases were included in the analysis.
Analytical approach
To calculate the cost-effectiveness of the implementation of the optimum continence service
specification, a decision analytical model was developed using Excel (Fig 1). The aim of the
model was to compare the total costs and health benefits of the current standard of care (cur-
rent care) for UI with an alternative standard of care approach that incorporates the optimum
continence service specification (new care). The new approach to care consists of more active
detection of patients with UI and the initial assessment and treatment by a nurse continence
specialist (NS). The potential improvement in tailoring the prescribed containment products
to the patient’s and carer’s needs and the potential improvement in case coordination were not
included in the current evaluation, as no studies were retrieved that quantified such effects.
The calculations of costs and health benefits were limited to a time horizon of 3 years. The
model was also used to perform a 3-year budget impact analysis.
Model structure
The structure of the decision analytic model was developed to reflect the entire pathway for UI
care in the Netherlands. All possible care pathways were identified by means of a series of inter-
views conducted with healthcare experts: 3 GPs, 3 pelvic physiotherapists, 2 continence nurses,
3 gynaecologists, 2 surgeons, 2 urologists, a geriatric specialist, a gastroenterologist, and a phar-
macist. The entire care pathway begins with the detection phase, where patients can be detected
Table 1. Characteristics of the target patient population.
Characteristics Estimate Source
Size of target patient population:
Number of community-dwelling elderly in the Netherlands (65
or older)
2,591,357 CBS [29]
% patients with 4 or more chronic diseases corrected for age
distribution
31% NIVEL [30]
Total number of community-dwelling elderly with 4
chronic diseases
808,503
Prevalence and incidence of UI in target patient population:
Yearly incidence rate for UI in elderly with 4 chronic
diseases
3.20% NIVEL [30]
Total number detected incident cases UI in elderly with
4 chronic diseases per year
25,872
% of elderly patients with self-reported symptoms of UI 25% Teunissen [3]
Total number prevalent cases UI in elderly with 4
chronic diseases per year
58306
Men 13,410
(23%)
CBS [29], Uijen [28],
Teunissen [3]
Women 44,896
(77%)
CBS [29], Uijen [28],
Teunissen [3]
doi:10.1371/journal.pone.0138225.t001
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by a GP or never be detected and remain incontinent. Patients who are never detected remain
in this category for the entire duration of the model. All detected patients continue on to the
initial assessment phase where the type and severity of incontinence is assessed. Initial assess-
ment in the Netherlands can be performed by either a GP or pelvic physiotherapist [31].
Patients then move to the treatment phase where they can enter one of three care pathways: 1)
treatment for cure alongside treatment for containment, where the aim is to reduce the number
of incontinence episodes as much as possible; 2) treatment for containment only, where the
patient receives a prescription for pad use but is not actively followed for improvement of
symptoms; or 3) self-management, where the patient is neither actively treated for cure nor
treated for containment.
Patients who enter the treatment for cure pathway flow into a Markov process where they
will move to one of three possible health states (Fig 2): 1) incontinent; 2) improvement, where
Fig 1. Decision analytic model structure. *M denotes Markov model structure.
doi:10.1371/journal.pone.0138225.g001
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patients experience at least 50% fewer incontinence episodes; and 3) success, where patients
experience 100% fewer incontinence episodes. All patients begin the first treatment cycle in the
incontinent health state. Each cycle in the model lasts 3 months. In the later cycles, patients can
move from the incontinent health state to the improvement or success health states. Patients
who enter the improvement health state can either remain in the improvement state or move
to the success state. Patients who enter the success state remain in the state for the duration of
the analysis.
The probability of moving between health states in the treatment for cure pathway is depen-
dent on the type of care a patient receives. Fig 3 describes the care pathway modelled on treat-
ment for cure. In this pathway, all patients are initially treated in the primary care setting (i.e.,
first-line) by the GP. The GP then decides, based on the type and severity of UI, whether the
Fig 2. Markovmodel structure.
doi:10.1371/journal.pone.0138225.g002
Fig 3. Care pathway for treatment for cure plus containment.
doi:10.1371/journal.pone.0138225.g003
Cost-Effectiveness of Continence Nurse Specialist
PLOS ONE | DOI:10.1371/journal.pone.0138225 October 1, 2015 6 / 23
patient should be referred immediately for pelvic physiotherapy or specialist care. Patients who
are not referred immediately are then treated by the GP with one of the following therapy
options: 1) medication; 2) lifestyle advice; 3) or treatment for urinary tract infection.
Patients who fail despite active treatment by the GP either remain incontinent and stop
receiving active treatment or are referred to the pelvic physiotherapist or specialist for a second
attempt at active treatment. Patients who are referred to the pelvic physiotherapist receive pel-
vic floor muscle training (PFMT) with or without biofeedback therapy. Patients who fail
PFMT are subsequently referred either to a specialist or back to the GP. Patients who are
referred to a specialist receive one of the following therapy options: 1) medication; 2) surgical
procedure; 3) referral to the pelvic physiotherapist for eligible patients who have not received
PFMT; 4) or other conservative therapy (for example, in the Netherlands occasionally pessaries
are prescribed). All patients who fail specialist care are referred back to the GP.
Patients who enter the two care pathways for treatment by containment only and self-man-
agement are assumed to remain incontinent and hence remain in the incontinence health state.
The only difference between these care pathways is that the costs of pad use for patients treated
by containment are reimbursed by the health insurer in the Netherlands, thus representing
costs borne by the health care system. The costs of pad use in the self-management pathway,
however, are assumed to be borne by the patient and are included as out-of-pocket costs.
Model of current care versus new care. The model structure and patient flow are essen-
tially the same for the current care and new care. However, in the new care strategy, the NS is
assumed to be active in finding patients who are incontinent, thus increasing the detection
rate. Also, instead of having an initial consultation with a GP or an immediate referral, patients
now start with a consultation with the NS, who will perform an initial assessment, establish a
diagnosis and start treatment on that basis. This may, or may not, include a prescription for
containment and may be followed by a “containment only” strategy. In the case of treatment
for cure, the NS will carry out three follow-up consultations that are used for training and life-
style advice. After that, the NS may refer patients to the pelvic physiotherapist and the special-
ist. We assumed that from then on, the pathway does not differ from the current care strategy.
The intervention has been described in more detail in S2 Appendix.
Input parameters
Patient flow and effectiveness of current care. Table 2 provides details on the input
parameters for transition probabilities used to model patient flow and the probability of treat-
ment effectiveness in terms of improvement or success. Values for input parameters were
taken from published literature wherever possible [32–36]; otherwise expert opinion was
sought. Details from the expert interviews can be found in Table 3, and information on the
search strategies applied in order to find relevant published studies can be found in S1 Appen-
dix [37].
Some transition probabilities differ between incident and prevalent patients. Incident
patients enter the care pathway at the start, whereas prevalent patients are already located
somewhere in the pathway. In order to estimate the distribution of prevalent patients over the
care pathway, we ran the model first with 100 hypothetical patients and checked where they
were after 1 year (i.e., not detected, successfully treated for cure, treated by containment or self-
care). Sixteen of these 100 patients had successfully been treated by that time and were no lon-
ger in the care pathway. The distribution of the remaining (now prevalent) patients is found in
Table 3.
Effectiveness of nurse specialist-led care. In our search for the effectiveness of nurse-led
incontinence care, we found 20 publications of studies, three of which were performed in a
Cost-Effectiveness of Continence Nurse Specialist
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Table 2. Input parameters used to model patient flow and treatment effectiveness.
Input parameter Current
care
New
care
Source
Detection
% incident cases detected by GP 50,40% 64% CC: Awareness study [45], NC:Assumption
Extra detection by NS 14% Awareness study [45].
% prevalent cases never detected but incontinent 62,80% 48,79% Derived with model
Initial assessment
% incident cases assessed/diagnosed by GP 95% 100% Assumption
% incident cases assessed/diagnosed by PPT 5% 0% Assumption
Treatment strategy
Treated for cure % incident cases 37% 39% Difference
Treated for cure % prevalent cases 0,01% 6,67% Derived with model
Containment only % incident cases 61% Expert opinion
Containment only % prevalent cases 36,00% 44,54% Derived with model
Self-management % incident cases 2% 0% Assumption
Self-management % prevalent cases 1,20% 0,00% Derived with model
Active treatment in patients treated for cure
GP
% of cases treated in cycle 1 by GP (incident population) 100% Assumption
% of cases being treated in cycle 1 by GP (prevalent population) 33% Assumption
Treatment decision by GP:
Immediate referral 51% Expert opinion and data.
To pelvic physiotherapist 57% Expert opinion and data.
To specialist 43% Expert opinion and data.
Immediate treatment attempt by GP 49% Difference
% receive training from GP 0% Expert opinion and data.
% training from GP with improvement 0% Expert opinion and data.
% training from GP with success 0% Expert opinion and data.
% receive medication from GP 79% Expert opinion
% meds from GP with improvement 63% Drutz et al. [32]
% meds from GP with success 16% Imamura et al. [4]
% users medication that receive 2nd cycle medication* 76% Sexton et al. [33]
% continue medications with improvement 80% Imamura et al. [4]
% continue medications with success 20% Drutz et al. [32]; Imamura et al. [4]
% receive lifestyle advice from GP 17% Expert opinion
% lifestyle advice from GP with improvement 10% Assumption
% lifestyle advice from GP with success 0% Assumption
% receive treatment for urinary infection from GP 4% Expert opinion
% treatment for infection from GP with improvement 40% Assumption
% treatment for infection from GP with success 10% Assumption
GP and NS
% of cases treated in cycle 1 by GP/NS (incident population) 100% Assumption
% of cases being treated in cycle 1 by GP /NS (prevalent
population)
33% Assumption
Percentage of cases initially treated by NS for 3 consults (i.e., first
cycle)
96% Difference
Cases treated initially by NS with improvement 21% Subak et al. [18]
Cases treated initially by NS with success 31% Subak et al. [18]
(Continued)
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Table 2. (Continued)
Input parameter Current
care
New
care
Source
% of cases that initially receive treatment for urinary infection 4% Expert opinion
Cases treated for infection by NS with improvement 80% Assumption
Cases treated for infection by NS with success 20% Assumption
% NP failures in cycle 1 continuing with NS care in cycle 2 40% Assumption
% receiving medication from NS 100% Expert opinion
Cases receiving meds from NS with improvement** 63% Drutz et al. [32]
Cases receiving med from NS with success 16% Imamura et al. [4]
Percentage users of medication under advice of NS that receive
2nd cycle of medication***
76% Sexton et al. [33]
Cases that continue with meds in cycle 3 with improvement 80% Drutz et al. [32]; Imamura et al. [4]
Cases that continue with meds in cycle 3 with success 20% Drutz et al. [32]; Imamura et al. [4]
% of failures of NS care that are referred 60% Assumption
To pelvic physiotherapist 33% Assumption
To specialist 67% Assumption
PT
% cases treated in cycle 1 by PPT (incident population) 0% Assumption
% cases being treated in cycle 1 by PPT (prevalent population) 33% Assumption
Treatment decision by PPT:
% receive PFMT training only 95% Expert opinion
Cases receiving PFMT with improvement 62% 37% Expert opinion.
Cases receiving PFMT with success 0% Expert opinion
% receive PFMT plus biofeedback 5% Expert opinion
Cases receiving PFMT plus biofeedback with improvement 45% Burns et al. [34]
Cases receiving PFMT plus biofeedback with success 23% Burns et al. [34]
% training patients with a success/improvement that continue 100% Assumption
Cases of training patients in the second cycle with improvement 44% 46% McFall et al. [35]
Cases of training patients in the second cycle with success 56% 54% McFall et al. [35]
% of failures of PPT treatment that are referred 100% Assumption
To GP 33% Expert opinion
To specialist 67% Expert opinion
Specialist
% cases treated in cycle 1 by specialist (incident population) 0% Assumption
% cases being treated in cycle 1 by specialist (prevalent
population)
33% Assumption
% cases referred immediately from specialist to PPT for training 40% Expert opinion.
% cases treated immediately by specialist 60% Difference
Treatment decision by specialist:
% receive surgery 17% Expert opinion
Cases receiving surgery with improvement 8% Expert opinion.
Cases receiving surgery with success 77% Labrie et al. [37]
% receive conservative therapy 2% Expert opinion.
Cases receiving conservative therapy with improvement 34% Richter et al. [36]
Cases receiving conservative therapy with success 0% Assumption
% receive medication from specialist 81% Expert opinion.
Cases receiving meds from specialist with improvement 63% Drutz et al. [32]
Cases receiving meds from specialist with success** 16% National Collaborating Centre for Women’s and
Children’s Health & NICE [14]
(Continued)
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population that differed from our population (UI in younger patients, postnatal UI and men
with UI after prostatectomy). In 9 of the 15 remaining studies an intervention comparable to
the optimum continence service specification was compared with usual care (by GPs) [18, 38–
44].
For the effectiveness of care provided by the NS we used the only study that reported the
percentage of patients who became continent and the percentage of patients who improved by
50% [18]. No information was found in the literature regarding the increase of the detection
rate. Therefore we used information from an international incontinence awareness study [45].
From that study, we assumed that the percentage of patients who stated that they had not vis-
ited their GP for incontinence problems but intended to do so in the future provided a reason-
able estimate of the potential increase in detection with a NS. This increase in detected patients
increases the pool of patients that may potentially be treated leading to success or improve-
ment. As mentioned previously, one of the tasks of the NS would be to improve case coordina-
tion (i.e. liaise with formal home care agencies, with other health practitioners, and with
informal caregivers) that may lead to improved effectiveness of new care, but probably also
leads to increased costs. This task has, however, not been quantified in the analysis due to lack
of evidence regarding its impact on health effects and costs.
Incontinence-related adverse events and use of formal home care and informal care.
The costs and health impact of disease-related adverse events were included in the analysis
alongside the use of medical and nonmedical home care support (Table 4). Disease-related
adverse events included fractures, skin breakdown and urinary tract infections (UTI). The inci-
dence of UTI was based on the difference between the yearly incidence of 1 or more episodes of
UTI in patients with overactive bladder (OAB) compared with patients with no OAB (45.7%-
15.4% = 30.3%), corrected for cycle length (8%) [15].
The incidence of fractures was derived from studies by de Rekeneire [46] and Hunter [47].
From these we estimated the percentage of falls attributable to incontinence per cycle (0.41%)
and the percentage of falls resulting in a fracture (5.7%) [48], resulting in a percentage fractures
per cycle of 0.023% (see S1 Appendix).
The incidence of skin breakdown was based on the findings of a 5% random sampling of the
1996–1997 California Medicaid Program (Medi-Cal) claims data in the U.S. which showed
that 8% of the OAB population received treatment for skin infections [49].
Table 2. (Continued)
Input parameter Current
care
New
care
Source
% users of medication that receive 2nd cycle of medication*** 76% Sexton et al. [33]
Cases continuing meds with improvement 80% Drutz et al. [32]; Imamura et al. [4]
Cases continuing meds with success 20% Drutz et al. [32]; Imamura et al. [4]
% failures of specialist treatment that are referred 100% Assumption
To GP 100% Assumption
To pelvic physiotherapist 0% Difference
GP: general practitioner, NS: continence nurse specialist, PPT: pelvic physiotherapist, PFMT: pelvic floor muscle training.
*Costs were valued based on the average daily dose of the following drugs used to treated urge UI: tolterodine, solifenacin, darifenacin, fesoterodine.
**Costs were valued based on average % of patients 'absolutely dry' after use of tolterodine IR, tolterodine ER, solifenacin, darifenacin, or fesoterodine.
***Costs were valued based on the average discontinuation rate from the studies that reported results at 9–12 months for the medications: tolterodine,
solifenacin, darifenacin, fesoterodine.
doi:10.1371/journal.pone.0138225.t002
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To incorporate the costs and benefits of the new care in terms of informal care (i.e. care
given by spouses, children, friends etc.) and formal home care (personal care, nursing care and
home help by paid care giver), the percentage of patients requiring care were taken from two
studies: a study by Langa et al. [50] in the U.S. which reported that 43% of elderly patients with
UI require informal care, and a study by Sorbye et al. [51] at 11 sites in Europe which reported
that 47% of UI patients require formal home care. Finally, to capture the cost-savings that
result from the reduction in informal care and home care use for patients who move from the
incontinence health state, we assumed that home patients experiencing improvement and suc-
cess used 10% and 25% less care than other patients, respectively.
Table 3. Probability inputs for current care based on expert opinion.
Parameters Number of experts Range Value used in model
Treatment strategy
Percentage of incident cases treated for containment only 3 GP and 1 database 33%-90% 61%
Cases treated for containment only with improvement 1 GP 0% 0%
Cases treated for containment only with success 1 GP 0% 0%
Active treatment in patients treated for cure
GP
Treatment decision by GP:
Immediate referral 3 GP and 1 database 20%-100% 51%
To pelvic physiotherapist 3 GP and 1 database 47%-100% 57%
To specialist 3 GP and 1 database 0%-53% 43%
Percentage that receive training from GP 3 GP and 1 database 0%-1% 0%
Percentage that receive medication from GP 3 GP and 1 database 0%-100% 79%
Percentage that receive lifestyle advice from GP 3 GP and 1 database 0%-59% 17%
Percentage that receive treatment for urinary infection from GP 4%
PFPT
Treatment decision by PFPT:
Percentage that receive PFMT training only 1 PFPT 95% 95%
Cases receiving PFMT with improvement 2 PFPT 50%-80% 62%
Cases receiving PFMT with success 2 PFPT 0% 0%
Percentage that receive PFMT plus biofeedback 1 PFPT 5% 5%
Percentage of failures of PT treatment that are referred Assumption 100%
Percentage of not improved patients referred back to GP 1 PFPT 33% 33%
Percentage of not improved patients referred back to specialist 1 PFPT 67% 67%
Specialist
Percentage cases referred immediately from specialist to PPT for training 2 Gynaecologists and 2 Urologists 16%-80% 40%
Percentage cases treated immediately by specialist 2 Gynaecologists and 2 Urologists 20%-84% 60%
Treatment decision by specialist:
Percentage receive surgery 2 Gynaecologists and 1 Urologist 17% 17%
Cases receiving surgery with improvement 1 Urologist* 8% 8%
Cases receiving surgery with success 1 Urologist + study Labrie et al [37] 78% + 76% 77%
Percentage receive conservative therapy 2 Gynaecologists and 1 Urologist 0%-4% 2%
Percentage receive medication from specialist 2 Gynaecologists and 1 Urologist 75%-100% 81%
GP: general practitioner; PPT: pelvic physiotherapist; PFMT: pelvic floor muscle training.
* Expert opinion was based on the average improvement rate of the ProAct and the TVT procedure
doi:10.1371/journal.pone.0138225.t003
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Costs. Costs were calculated from a societal and health care perspective. To calculate the
total costs per comparator from the societal perspective all types of costs were included, i.e.
medical treatment, consultations, containment products (both paid by insurer and out-of-
pocket), incontinence-related adverse events such as fractures, skin breakdown and urinary
tract infection, formal home care, informal care and travel costs (Table 5). Productivity costs
(indirect non-medical costs) were not included since the target patient population was of
retirement age. For the health care payer perspective, the informal care costs, travel costs and
out-of-pocket costs for containment products were excluded. All costs were reported in terms
of 2013 euros with historical prices corrected for inflation where necessary.
Costs are generally estimated by combining resource use with a cost per unit of care. The
Dutch costing manual was used to value the costs of travel, hours of formal home care, hours
of informal care and consultations [52], with the exception of NS consultations, which were
based on a pro-rated hourly wage [53]. To calculate the hourly wage for NSs, an annual salary
of €44,736, which was based on an average monthly salary of €3,728 (Functional scale 60, step
5), was divided by 1,540, which are the average number of workable hours per year assuming a
36-hour week.
The average weekly use of informal care was taken from a US study on informal caregiving
time in a group of patients with pad use [50], which was corrected for the proportion of males
and females in the target patient population. Formal home care was estimated based on the
average number of hours of personal home care for the elderly in the Netherlands [54, 55].
Where possible, the costs of medical treatment and incontinence-related events were taken
from publicly available tariffs made available from the Dutch Healthcare Authority (NZA) [56]
or the National Health Care Institute (former CVZ) [57], and otherwise taken from published
literature. The costs of containment pads for patients in the incontinent and improvement
health states were valued based on the reimbursement price and average daily use which was
adapted according to a scale for severity of UI symptoms and the corresponding daily pad use
[55]. Patients in the success health state were assumed to have no or negligible pad use. Out-of-
pocket costs for containment products for incontinent patients who were never detected and
patients who manage their incontinence with self-care were included and were based on the
costs applied to incontinent patients.
For new care we also included implementation costs, which were based on the cost to edu-
cate and train 500 NSs calculated on the basis of 4000 GP locations in the Netherlands with 1
NS visiting 8 locations per week. We assumed that the total training costs can be depreciated
Table 4. Incidence of disease-related adverse events and use of medical and nonmedical support.
Input parameter Estimate Source
Incidence of disease-related adverse events
Urinary tract infections (per 3 months) 8% Hu and Wagner [15]
Fractures (per 3 months) 0.02% de Rekeneire [46]; Hunter [47]; Meerding
et al. [48]
Skin breakdown (per 3 months) 8% Brown et al. [49]
Medical and nonmedical support needs
Percentage users of informal care 43% Langa et al.[50]
Percentage users of formal care 47% Sorbye et al. [51]
% reduction use of formal or informal care in
improved cases
10% Assumption
% reduction use of formal or informal care in
success cases
25% Assumption
doi:10.1371/journal.pone.0138225.t004
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over a period of 5 years. For the base case analysis, we included 23.8% of the total training
costs, as the target population of the current analysis reflects approximately 23.8% of the total
UI and FI population in the Netherlands (see S2 Appendix) and, once trained NS are working
within a GP practice, they will also take on the care for other UI and FI patients. However, in a
scenario analysis we explored how the results change when all implementation costs are
assigned to the current target population.
Table 5. Cost and utility parameters included in the model.
Input parameter Base case value Source
Quality of Life
Utility in success health state 0.8595 Slieker-ten Hove et al. [58]
Utility in improvement health state 0.84205 Assumption
Utility in failure health state 0.8246 Slieker-ten Hove et al. [58]
Direct medical costs (2013 euro) Cost per cycle
Consultation GP € 30.48 Hakkaart-van Roijen et al. [52]
Consultation NS € 41.39 Salary per month (FWG 60, step 5) [53]
Cost medication use under care of GP or NS € 114.96 Health Care Institute [57]
Cost lifestyle advice under care of GP € 30.48 Hakkaart-van Roijen et al. [52]
Cost training under care of GP € 30.48 Hakkaart-van Roijen et al. [52]
Cost treatment of infections under care of GP € 2.51 National Health Care Institute. [57]
Consultation PPT € 39.19 Hakkaart-van Roijen et al. [52]
Cost PFMT training with PPT € 205.73 Expert opinion.
Cost training plus biofeedback/electro stimulation with PPT € 216.23 Expert opinion.
Consultation specialist € 130.62 Dutch Healthcare Authority (NZa). [56, 56]
Cost surgery under care of specialist € 317.97 Dutch Healthcare Authority (NZa). [56, 56]
Cost medication under care of specialist € 317.16 Dutch Healthcare Authority (NZa). [56, 56]
Cost conservative therapy under care of specialist € 137.74 Dutch Healthcare Authority (NZa). [56, 56]
Cost containment pads success cases €- Reimbursement price, Achmea [55]
Cost containment pads improved cases € 71.22 Reimbursement price, Achmea [55]
Cost containment pads failure cases € 97.70 Reimbursement price, Achmea [55]
Cost of treating UTI € 2.51 Hakkaart-van Roijen et al. [52]
Cost of surgery for fractures € 2,944.36 Meerding et al. [48]
Cost of skin breakdown € 6.49 Market price of Sudocrem
Cost of formal care, success cases € 2,894.53 Eggink et al. [54]; Reimbursement price, Achmea [55]
Cost of formal care, improved cases € 3,473.44 Eggink et al. [54]; Reimbursement price, Achmea [55]
Cost of formal care, failure cases € 3,859.38 Eggink et al. [54]; Reimbursement price, Achmea [55]
Direct nonmedical costs (2013 euro)
Travel costs GP/NP € 3.51 Hakkaart-van Roijen et al. [52]
Travel costs PPT € 13.94 Hakkaart-van Roijen et al. [52]
Travel costs Specialist € 4.79 Hakkaart-van Roijen et al. [52]
Cost informal care success cases € 1,596.75 Hakkaart-van Roijen et al. [52]
Cost informal care improved cases € 1,916.09 Hakkaart-van Roijen et al. [52]
Cost informal care failure cases € 2,128.99 Hakkaart-van Roijen et al. [52]
Indirect costs (2013 euro)
Out-of-pocket costs of containment pads € 97.70 Reimbursement price, Achmea [55]
Implementation cost of new care per year € 426,496.00 See S2 Appendix
GP: general practitioner, PPT: pelvic physiotherapist, NS: continence nurse specialist, UTI: urinary tract infections.
doi:10.1371/journal.pone.0138225.t005
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Health benefits. Health benefits were expressed in quality-adjusted life years (QALYs),
where a quality of life weight is given to each of the 3 health states defined. To calculate
QALYs, utility values were applied to the time patients spent in the various health states of suc-
cess, improvement and incontinence (Table 5). The utility values applied in the model were
taken from a cross-sectional study of quality of life using a EQ-5D questionnaire in a general
female population aged 45–85 in the Netherlands [58]. The utility of patients with improve-
ment was based on the average of the utility of patients with success (continent) and the utility
of patients with UI.
Budget impact analysis
For the budget impact analysis, the population considered consists for the first year of all prev-
alent and incident patients. In the second year, new incident cases are added, whilst patients
already in the pathway may exit the model either because they die or they move to a nursing
home. The same applies to the third year: new cases flow into the pathway, other patients are
removed from the pathway. Mortality was estimated using Dutch life tables [29]. From these
we found the probability of dying in the subsequent 1, 2 or 3 years for patients in all the rele-
vant age bands. Unfortunately we did not have data specific to patients with at least 4 chronic
diseases, so the mortality rates used for the budget impact analysis are likely to be a slight
underestimate.
The percentage of patients moving to a nursing home per year was estimated at 4% (see S2
Appendix for the calculation).
Assessment of uncertainty
The influence of parameter uncertainty on the results was assessed by one-way sensitivity anal-
ysis (OWSA) and probabilistic sensitivity analysis (PSA). In the OWSA, each parameter was
varied within a range of plus or minus 40% of the mean value. A PSA was performed to assess
the level of confidence surrounding the decision in which the values of all parameters are
simultaneously allowed to vary. For the PSA, cost parameters were allowed to vary within a
range of plus or minus 20% of the mean value. A beta distribution with a standard error equal
to 20% of the mean was applied in the PSA for all parameters limited to the interval of 0 and 1,
such as transition probabilities and utilities. For all other parameters, a uniform distribution
was assumed. In a separate PSA we also used a percentage of 40% instead of the more com-
monly used 20% in order to account for the low level of evidence used in this model (e.g. the
parameter estimates that were based on the expert opinion).
Scenario analysis
A scenario analysis was conducted to assess the impact of assuming that the full 100% rather
than 23.8% of the implementation costs are included in the costs of new care.
In addition, we explored the impact of the effectiveness of the NS in two scenarios: 1) new
care has impact only on the detection rate and not on the effectiveness of the care; 2) new care
has impact only on the effectiveness of care but not on detection.
Results
Base case
The analyses showed that for the incident patient group, 9% of patients will be successfully
treated in the usual care pathway, versus 14% of patients in the new care pathway (see Table 6).
In addition, the percentage of patients that is improved increases by 3%. For the prevalent
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patients, the extra detection of patients by the NS leads to 4% of patients now being successfully
treated and 3% of patients showing an improvement.
Looking at costs and health benefits, we see that the new care strategy is cost-saving com-
pared with usual care, with an average savings of €402 per patient from a societal perspective
(Table 7). When the perspective is limited to the health care payer perspective, an average cost
saving of €97 per patient is achieved over the three year time frame. At the same time, on aver-
age a small gain in quality of life (0.005) is achieved.
Overall, the increased percentages of successfully treated and improved patients reduce the
costs of formal home care, informal care and containment products. However, some of the
costs for containment are now shifted from out-of-pocket costs for the patient to costs for the
health insurer.
Budget impact
In addition to the per patient analysis, we also looked at the budget impact of the optimum
continence service specification on a national level. Over a 3 year period, the total savings
would amount to € 29 million from a payer perspective and € 117 million from a societal per-
spective (see Table 8).
Sensitivity analysis
Results from the OWSA are presented in Fig 4, showing the impact of influential parameters
on the estimate for incremental costs. While the range of incremental costs consistently fall
Table 6. Outcomes, percentages successfully treated and improved patients.
Incident group Prevalent group
Usual care New care Incremental Usual care New care Incremental
% success 9% 14% 5% 0% 4% 4%
% improved 8% 11% 3% 0% 3% 3%
% not improved 84% 76% -8% 100% 94% -6%
doi:10.1371/journal.pone.0138225.t006
Table 7. Costs and QALYs per patient per 3 years.
Usual care New care Difference
GP (+NS) € 20 € 47 € 27
Pelvic physiotherapist € 14 € 13 € -1
Specialist € 25 € 26 € 0
Containment (insured) € 436 € 563 € 127
UI-related adverse events € 16 € 16 € -1
Home care € 21,576 € 21,323 € -253
Implementation costs € - € 5 € 5
Total health care costs € 22,088 € 21,991 € -97
Out-of-pocket costs* € 700 € 523 € -177
Informal care costs € 10,889 € 10,761 € -128
Total societal costs € 33,677 € 33,276 € -402
Total QALYs 2.4777 2.4829 0.005
*Note that over 99.9% of out-of-pocket costs are for containment products. The remaining costs are travel costs.
doi:10.1371/journal.pone.0138225.t007
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below zero, i.e., cost-saving, the magnitude of cost-savings is influenced by a number of param-
eters. The most influential parameters include estimates associated with the effectiveness of
new care. Cost-savings are increased as the percentage of patients receiving treatment for cure
by the NS increases, the detection rate of UI patients attributable to the NS increases, and the
success rate of NS care increases. Other influential factors include the costs and frequency of
use of both formal and informal care in current care and the out-of-pocket costs of contain-
ment products for patients who manage their incontinence with self-care. The influence of
direct costs outside the health care sector underscores the need to consider the societal costs
when performing economic evaluations of UI care.
The results of the PSA (with a SE of 20% of the mean) show a 95% range of incremental
costs from a saving of €911 to additional costs of €41, with a 96% probability of cost savings.
For incremental QALYs, the 95% range varies from -0.0005 to 0.013, and a 5% probability of
fewer QALYs. Also, the PSA results show that, with 95% certainty, the new care intervention
dominates current care i.e. it is more effective and cost-saving. For the PSA with increased
uncertainty (with a SE of 40% of the mean) we found an 80% probability of cost saving and a
22% probability of fewer QALYs. The overall probability that the new care intervention would
dominate the current care was now 75%.
Scenario analyses
The impact of the assumption that 100% rather than 23.8% of the implementation costs are
included in the costs of new care was shown to be of little influence on the cost-savings. The
results for cost-savings were slightly lower compared with the base case at €387 and €83 from
the societal and healthcare perspective, respectively.
Table 8. Budget impact over a period of 3 years.
New care Usual care Incremental
Societal perspective € 9,505 M € 9.622 M - € 117 M
Health care payer perspective € 6.282 M € 6.311 M - € 29 M
M = Million
doi:10.1371/journal.pone.0138225.t008
Fig 4. Diagram depicting the impact of influential parameters on the cost-savings.
doi:10.1371/journal.pone.0138225.g004
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When we assume that new care has impact only on the detection rate and not on the effec-
tiveness of the care, we find that the QALYs gained reduce to 0.004 whilst from a societal per-
spective costs are still saved (€-203). From a health care perspective we now observe a cost
increase of € 58. In that latter situation, the ICER is €14,500 per QALY gained. When we look
at the reverse scenario in which the NS has an impact on the success rate but is not able to
detect more patients the QALYs gained reduce to 0.001, with a cost saving of €109 and €65
from a societal and health care perspective, respectively.
Discussion
Our study has shown that with the new care strategy, with a nurse specialist located in primary
care, a small gain in quality of life is achieved. This increase in quality of life is achieved at
reduced cost compared with usual care, with an average saving of €402 per patient over a 3
year period from a societal perspective. When the perspective is limited to the health care payer
perspective, an average cost saving of €97 per patient is achieved over the three year time
frame. In interpreting these findings it is important to realise that many patients are unde-
tected, even in the new care situation (36%), or receive treatment for containment only. In
both of these groups it is assumed that no cure or improvement of the UI will be achieved.
The results of our study are based on the effectiveness of a NS in the RCT by Subak et al.
[18]. Previous studies have shown conflicting evidence for the benefits of a nurse-led interven-
tion for UI. A meta-analysis of 11 randomised trials comparing nurses with GPs showed no
benefit in terms of health outcomes, although little data on the cost impact were available in
these trials [59]. More recent studies of nurse-led continence care were conducted alongside
randomised controlled trials. Two were conducted in the UK [60, 61] and the third in the
Netherlands [62]. The earlier study from the UK presents findings that conflict with those used
in the present study. Moore et al. [60] studied standardised conservative therapy regimens pro-
vided by nurse continence advisors versus urogynaecologists in 110 consecutive women with
mild or moderate urinary leakage. The authors found that the reduction in urine leakage and
improvement in quality of life observed in patients treated by nurse continence advisors and
urogynaecologists were similar at 12 weeks and 2 years but that lower costs arose from treat-
ment provided by nurse advisors. The conflicting results for health benefits could be explained
by the difference in the comparator used. In the present study the nurse led intervention was
compared with the care as usual by the GP who, according to interviews with experts, in gen-
eral does not provide PFMT and bladder training. In the study of Moore et al. [60], the urogy-
naecologists did provide these. Also, due to the high drop-out rate of their study (24%), the
authors encouraged caution in the interpretation of their findings. A more recent study in the
UK byWilliams et al. [61] evaluated the impact of a new service led by a continence nurse
practitioner compared with existing primary/secondary care provision for men and women
aged 40 or above with urinary incontinence and storage symptoms. The authors found that the
continence nurse practitioner-led intervention improved health outcomes through reduced
symptoms at 3 and 6 months; impact was reduced; and satisfaction with the new service was
high. At 6 years of extended follow-up, the health benefits of the nurse-led intervention group
remained significant compared with the control group [42]. Williams et al. [61] found the costs
to increase with nurse-led care. However, they did not include the costs of formal home care
and informal care, which we have shown to be an influential factor in realising cost-savings.
Findings from a study performed in the Netherlands by Albers-Heitner et al. [62] demon-
strated that although a nurse-led intervention increased QALYs compared with care-as-usual,
it was more expensive due to the additional implementation costs. These findings were, how-
ever, limited to 12-month outcomes. Extending the timeframe of the analysis beyond one year,
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as was done in the present study, could produce different results if the implementation costs
were assumed to be one-off costs for investing in the new care approach. More importantly,
just as in the study of Williams et al (2011), Albers-Heitner [62] did not include the costs of
formal home care and informal care in which a cost-reduction is expected. The costs of inconti-
nence-related adverse events were also not taken into account. Comparison between the results
presented here and that of previous studies should be viewed carefully since the methodology,
type of nurse-led intervention and target patient populations are not entirely comparable.
The potential effects of a nurse-led intervention for UI related to improvement in tailoring
prescribed containment products to the patient’s and caregiver’s’ need and a potential
improvement in case coordination have not been taken into account in the current analysis.
Although one of the authors mentioned above reported some information on the proportion of
patients receiving special information about adequate use of containment products by a NS,
this study did not provide enough information to estimate its effect on the costs and quality of
life per health state [63]. An improved tailoring of containment products could either increase
or decrease the costs for containment products but could be expected to increase a patient’s
quality of life and reduce the work load for informal care givers. In addition, the presence of a
NS who can coordinate care between the various health care professionals may lead to either
an increase or decrease of resource use. In the event of an increase, this would be likely to be
associated with a gain in quality of life for some patients.
In our study, health effects were expressed in quality-adjusted life years. This means that
utility weights were assigned to the health states: incontinent, improved and success (i.e. conti-
nent). Our values were taken from a survey among people aged between 40 and 80 years. Thus,
these utilities may not be fully applicable to our population of older persons with at least 4 co-
existing morbidities. However, for the calculation of QALYs gained with new care the decre-
ment of people with incontinence versus continence is more important than the absolute value.
In various studies with interventions in incontinence utilities have been measured and, regard-
less of the intervention (medication, surgery, physiotherapy), a similar decrement to the one
applied here was observed [64–66]. It should be realised that there may be gains for patients
beyond those measured in generic quality-of-life instruments such as the EuroQol EQ-5D [67].
For example, incontinence may hinder patients in carrying out activities such as volunteer
work or informal care giving. If patients can be socially active when they become continent
again or better manage their incontinence, society as well as the individual will benefit.
The sensitivity analysis demonstrated a few key parameters contributing to the uncertainty
surrounding the results. While it was shown that the results for cost-savings were generally
robust, the magnitude of possible cost-savings is greatly influenced by the assumptions made
regarding the effectiveness of new care and the need for medical and non-medical home care
support. The impact of introducing a nurse specialist into the care of UI patients in the Nether-
lands is unknown both in terms of its effectiveness and the use of formal home care and infor-
mal care. Given the potential for cost-savings and the possibility of achieving savings of up to
€911 per patient, further research into the impact of a NS both on patient outcomes and
resource use in the treatment of UI in the Netherlands would be worthwhile.
An important limitation of our current model of the care pathway is that we assumed that
patients who had achieved a complete or partial success would stay in that health state for the
duration of the model. Given the age of the population considered in our study, it seems likely
that over time some patients may become incontinent again. However, a recent review of the
long term effectiveness of pelvic floor muscle training showed that at least a substantial propor-
tion of patients remained continent or in their improved state. Given the relatively short time
horizon of our model, the impact of a small group of patients becoming incontinent again is
likely to be small [68].
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This relatively short time horizon of our model might be another limitation of our study.
Although none of the patients still received treatment at the end of our 3-year time horizon,
and thus the large majority of costs and health effects are captured in our model, it will proba-
bly not capture all costs and health effects. Patients who did not become continent after the
first three years, will probably keep using containment products and some patients who
became continent might become incontinent again and vice versa (Kondo et al). Since informa-
tion about relapse rates and spontaneously becoming continent was not available for our popu-
lation, we considered a longer time horizon highly speculative.
The current evaluation only considered one subset of all people with incontinence. Once
continence nurse-specialists are introduced in primary care, they can of course also take on the
care for other incontinent patients, and it might be interesting to explore the economic impact
of this. This is especially true for the group with faecal or double incontinence. However, we
found that the feasibility of adapting the model used in this study to the care of FI was limited
by the complete lack of any studies regarding a nurse-led intervention for FI. In addition, the
care pathway is more complex (using a multi-component approach) for these patients and it is
less clear what constitutes a (partial) success in treatment [1].
It is important to realise that the current results are specific for the Netherlands, where GPs
function as gatekeepers to specialist care and thus play a key role in the treatment of inconti-
nence. A number of options were considered for the choice of the healthcare professional tak-
ing the lead role. In the Netherlands there are varying levels of continence training for nurses.
The introduction of continence nurse specialists, rather than advanced practice nurses or other
relevant clinical providers may be a more expensive model but it was felt that this level of nurse
would provide the greatest clinical benefit and best fitted the Netherlands health service.
In countries where nurse specialists play a more important role in patient care or staff with
an equivalent specialist continence training or other relevant background are unavailable,
other treatment pathways will need to be defined and the activities of the healthcare profession-
als specified. The number of patients treated by GP, specialist or pelvic physiotherapist may
differ, resulting in different costs and potentially also different outcomes. This also means that
the best person to take on the coordinating role may vary between countries, which may in
turn affect both the additional costs and the achieved effects of implementing the changes rec-
ommended by the optimum continence service specification.
It should be realised that, in the Netherlands, the role of continence nurse specialists is still
quite new, with few nurses having completed this training. Thus, it will take a few years before
these continence NS can start to deliver continence care on a large scale.
In conclusion, implementing the optimum continence service specification in the Nether-
lands by having a continence nurse specialist in the GP practice is likely to reduce the level of
incontinence, improve quality of life, and reduce costs—from a payer’s perspective as well as
from the patient’s and carer’s perspective. The total budget savings may even increase as the
population ages. At the same time, the current study has shown that various areas of the incon-
tinence care process lack data, and thus it would be important to introduce the continence
nurse specialists in a study setting.
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